Daewoong Pharmaceutical presented the multiracial phase 1 clinical test results of ‘DWP14012,’ a drug for gastroesophageal reflux disease, at the United European Gastroenterology (UEG Week).

Daewoong Pharmaceutical presented the multiracial phase 1 clinical test results of ‘DWP14012,’ a drug for gastroesophageal reflux disease, at the United European Gastroenterology (UEG Week).